Seattle Genetics (SGEN -1.9%) is all over the board today after being pelted with news-related...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN -1.9%) is all over the board today after being pelted with news-related issues. Initially, the stock popped after announcing it had struck a new antibody drug conjugate collaboration deal with Bayer (BAYRY.PK) worth up to $520M, only to collapse on reports that it had temporarily halted studies of its Lymphoma drug Adcetris due to safety concerns over reports of pancreatitis.